Chemotherapy Effect Clinical Trial
Official title:
A Prospective, Single-arm, Phase II Study of PD-1 Inhibitor Combined With Ifosfamide, Carboplatin, and Etoposide (ICE) in the Treatment of Relapsed/Refractory Gray Area Lymphoma
There are no standard chemotherapy regimens for relapse/refractory gray area lymphoma. The programmed cell death ligand 1 (PD-L1) encoding gene is located in 9p24.1, so it is speculated that the programmed cell death pathway plays an important role in gray area lymphoma formation by evading immune surveillance in GZL.The purpose of this study was to evaluate the efficacy and safety of PD-1 monoclonal antibody combined with ICE in the treatment of patients with relapsed/refractory gray area lymphoma.
The purpose of this study was to evaluate the efficacy and safety of PD-1 monoclonal antibody combined with ICE in the treatment of patients with relapsed/refractory gray zone lymphoma. The main study endpoint is the Objective Response Rate (ORR), including Complete Remission Rate (CRR) and Partial Remission Rate (PRR), was evaluated according to Lugano2014 lymphoma efficacy evaluation criteria. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06376604 -
Fasting Mimicking Diet in Chemotherapy of Gynecologic Malignancies
|
N/A | |
| Completed |
NCT03753542 -
Effect of Nurse-led Education on Parent's Anxiety and Depression on Managing Side Effects of Chemotherapy
|
N/A | |
| Not yet recruiting |
NCT05022628 -
Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma Thrombosis
|
Phase 4 | |
| Completed |
NCT04207359 -
Effects of Creatine Supplementation in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT04489173 -
TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer
|
Phase 2 | |
| Completed |
NCT04173195 -
Comfort Talk (CT) During Outpatient Chemotherapy
|
N/A | |
| Recruiting |
NCT06041477 -
Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
|
Phase 3 | |
| Recruiting |
NCT05014399 -
Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy
|
||
| Recruiting |
NCT03275194 -
HIPEC in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy
|
Phase 2 | |
| Recruiting |
NCT04808466 -
Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy
|
Phase 2 | |
| Completed |
NCT05131490 -
Effect on Adaptation to Cancer of Mobile Application Developed for Gynecological Cancer Patients
|
N/A | |
| Completed |
NCT04118322 -
The Effect of Peppermint Oil on Nausea, Vomiting and Retching in Cancer Patients Undergoing Chemotherapy
|
N/A | |
| Recruiting |
NCT06043999 -
Salvage Chemotherapy Versus Total Mesorectal Resection for Local Resection Rectal Cancer Patients
|
N/A | |
| Recruiting |
NCT05515796 -
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
|
Phase 2 | |
| Not yet recruiting |
NCT04845490 -
Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy
|
Phase 2 | |
| Recruiting |
NCT04989985 -
S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction Adenocarcinoma
|
Phase 2 | |
| Recruiting |
NCT05424692 -
Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer
|
N/A | |
| Recruiting |
NCT05992337 -
New Biomarkers in the Prediction of Chemotherapy-induced Cardiotoxicity.
|
||
| Enrolling by invitation |
NCT04027478 -
Can Fasting Decrease the Side Effects of Chemotherapy?
|
N/A | |
| Completed |
NCT04116138 -
Antisecretory Factor in Primary Glioblastoma 1
|
Phase 1/Phase 2 |